KalVista Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-3.137; its P/E ratio is -3.53; KalVista Pharmaceuticals is scheduled to report earnings on July 4, 2024, and the estimated EPS forecast is $-0.70. See an overview of income statement, balance sheet, and cash flow financials.

	Jan 24	Oct 23	Jul 23	Apr 23	Jan 23
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	$ -29.03M	$ -27.65M	$ -25.32M	$ -26.30M	$ -21.30M
EBITDA	$ -28.82M	$ -27.43M	$ -25.06M	$ -26.04M	$ -20.89M
Net Income Common Stockholders	$ -29.03M	$ -27.65M	$ -25.32M	$ -26.30M	$ -21.30M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 75.59M	$ 103.17M	$ 123.26M	$ 149.38M	$ 171.69M
Total Assets	$ 113.97M	$ 138.74M	$ 160.33M	$ 183.23M	$ 203.47M
Total Debt	$ 7.44M	$ 7.69M	$ 7.99M	$ 8.23M	$ 8.48M
Net Debt	$ -68.14M	$ -95.48M	$ -115.27M	$ -141.14M	$ -163.21M
Total Liabilities	$ 25.39M	$ 24.30M	$ 21.00M	$ 22.18M	$ 19.03M
Stockholders Equity	$ 88.58M	$ 114.45M	$ 139.33M	$ 161.01M	$ 184.44M
Cash Flow	-
Free Cash Flow	$ -27.59M	$ -19.83M	$ -26.74M	$ -22.72M	$ -9.30M
Operating Cash Flow	$ -27.57M	$ -19.82M	$ -26.73M	$ -22.65M	$ -9.29M
Investing Cash Flow	$ -6.70M	$ 28.56M	$ 19.61M	$ -6.21M	$ -2.52M
Financing Cash Flow	$ 284.00K	$ 128.00K	$ 204.00K	$ -33.00K	$ 57.81M

Currency in USD

KalVista Pharmaceuticals Earnings and Revenue History

Income Statement >

KalVista Pharmaceuticals Debt to Assets

Balance Sheet >

KalVista Pharmaceuticals Cash Flow

Cash Flow >

KalVista Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing